Comparative Pharmacology
Head-to-head clinical analysis: CUPRIMINE versus CUVRIOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIMINE versus CUVRIOR.
CUPRIMINE vs CUVRIOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
300 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
Category C
Category C
Chelating Agent
Chelating Agent